Triphenyltin inhibition of the proteasome activity and its influence on substrate protein levels in nerve cells

Chinese Science Bulletin

Volumn 55, Issue 1, 2010, Pages 22-26

  Chen, Xi ^a   Shi, Guo Qing ^a   Zhong, Guang Rong ^a   Chen, Juan ^a   Lin, Sen ^a   Sun, Qing ^a  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY BEIJING   (China)

Author keywords

synuclein; Parkinson's disease; Proteasome; Triphenyltin

Indexed keywords

EID: 75649110805     PISSN: 10016538     EISSN: 18619541     Source Type: Journal    
DOI: 10.1007/s11434-009-0678-1     Document Type: Article

References (27)

1. Harino H, Ohji M, Wattayakorn G, et al. Accumulation of organotin compounds in tissues and organs of dolphins from the coasts of Thailand. Arch Environ Contam Toxicol, 2008, 54: 145-153.
2. Hoch M. Organotin coumpounds in the environment-an overview. Appl Geochem, 2001, 16: 719-743.
3. Zhang Z, Hu J, Zhen H, et al. Reproductive inhibition and transgenerational toxicity of triphenyltin on Medaka (Oryzias latipes) at environmentally relevant levels. Environ Sci Technol, 2008, 42: 8133-8139.
4. Grote K, Hobler C, Andrade A J, et al. Effects of in utero and lactational exposure to tributyltin chloride on pregnancy outcome and postnatal development in rat offspring. Toxicology, 2007, 238: 177-185.
5. Shunji U, Takashige K, Nobuyyki S, et al. Effects of butyltin compounds on mitochondrial respiration and its relation to hepatotoxicity in mice and Guninea pigs. Toxicol Sci, 2003, 75: 201-207.
6. Ohhira S, Matsui H. Comparative study of the metabolism of triphenyltin in hamsters and rats affter a single oral treatment with triphenyltin chloride. Toxicol Lett, 1996, 85: 3-8.
7. Nutt J G, Wooten G F. Clinical practice Diagnosis and initial management of Parkinson's disease. N Engl J Med, 2005, 353: 1021-1027.
8. Elbaz A, Bower J H, Maraganore D M, et al. Risk tables for parkinsonism and Parkinson's disease. J Clin Epidemiol, 2002, 55: 25-31.
9. de Rijk M C, Launer L J, Breteler M M, et al. Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the elderly research group. Neurology, 2000, 54: S21-S23.
10. Birkmayer W, Hornykiewicz O. The L-3, 4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia. Wien Klin Wochenschr, 1961, 73: 787-788.
11. Forno L S. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol, 1996, 55: 259-272.
12. Gandhi S, Wood N W. Molecular pathogenesis of Parkinson's disease. Hum Mol Genet, 2005, 14: 2749-2755.
13. Savitt J M, Dawson V L, Dawson T M. Diagnosis and treatment of Parkinson disease: Molecules to medicine. J Clin Invest, 2006, 116: 1744-1754.
14. Sun F, Kanthasamy A, Anantharam V, et al. Environmental neurotoxic chemicals-induced ubiquitin proteasome system dysfunction in the pathogenesis and progression of Parkinson's disease. Pharmacol Ther, 2007, 114: 327-344.
15. McNanght K S, Olanow C W, Halliwdl B, et al. Failure of the ubiquitin-proteasome system in Parkinsons's disease. Nat Rev Neurosci, 2001, 2: 289-294.
16. Dinis-Oliveira R J, Remiao F, Carmo H, et al. Paraquat exposure as an etiological factor of Parkinsons's disease. Neurotoxicology, 2006, 27: 1110-1122.
17. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature, 1998, 392: 605-608.
18. Goldberg A L. Functions of the proteasome: From protein degradation and immune surveillance to cancer therapy. Biochem Soc Trans, 2007, 35: 12-17.
19. Goldberg A L. Functions of the proteasome: The lysis at the end of the tunnel. Science, 1995, 268: 522-523.
20. Heinemeyer W, Fischer M, Krimmer T, et al. The active sites of the eukaryotic 20s proteasome and their involvement in subunit precursor processing. J Biol Chem, 1997, 272: 25200-25209.
21. Shi G, Chen D, Zhai G, et al. The proteasome is a molecular target of envronmental toxic organotins. Environ Health Perspect, 2009, 117: 378-386.
22. Ding Q, Dimayuga E, Martin S, et al. Characterization of chronic low level proteasome inhibition on neuronal homeostasis. J Neurochem, 2003, 86: 489-497.
23. Faneng S, Vellareddy A, Calivarathan L, et al. Dieldrin induces ubiquitin-proteasome dysfunction in α-synuclein overexpressing dopaminergic neuronal cells and enhances susceptibility to apoptotic cell seath. J Pharmacol Exp Ther, 2005, 315: 69-79.
24. Gao G, Dou Q P. N-terminal cleavage of bax by calpain generates a potent proapoptotic 18-kDa fragment that promotes bcl-2-independent cytochrome C release and apoptotic cell death. J Cell Biochem, 2000, 80: 53-72.
25. Balaban C D, O'Callaqhan J P, Billingsley M L. Trimethyltin-induced neuronal damage in the rat brain: comparative studies using silver degeneration stains, immunocytochemistry and immunoassay for neuronotypic and gliotypic proteins. Neuroscience, 1988, 26: 337-361.
26. Oluwatosin-chiqbu Y, Robbins A, Scott C W, et al. Parkin suppresses wild-type alpha-synuclein-induced toxicity in SHSY-5Y cells. Biochem Biophys Res Commun, 2003, 309: 679-684.
27. Su Y, Deng Y L, Qing H. Molecular mechanism of NF-κB in learing, memory and neurodegenerative diseases (in Chinese). J Medic Molecul Biol, 2008, 5: 432-435.